Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904

European Neuropsychopharmacology

Volumn 22, Issue 10, 2012, Pages 761-768

  Banasikowski, Tomek J ^a   Beninger, Richard J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Catalepsy; Conditioned catalepsy; Context dependency; Dopamine d3 receptors; Motivation; Sensitization

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; N [4 [4 (2,3 DICHLOROPHENYL) 1 PIPERAZINYL]BUTYL] 9H FLUORENE 2 CARBOXAMIDE; NAFADOTRIDE; NGB 2904; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE;

ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORENES; HALOPERIDOL; MALE; MOTOR ACTIVITY; NAPHTHALENES; PIPERAZINES; PYRROLIDINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPATIAL BEHAVIOR; TIME FACTORS;

EID: 84865564834     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.004     Document Type: Article

References (52)

1. Amtage J., Schmidt W.J. Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav. Pharmacol. 2003, 14:563-567.
2. Audinot V., Newman-Tancredi A., Gobert A., Rivet J.M., Brocco M., Lejeune F., Gluck L., Desposte I., Bervoets K., Dekeyne A., Millan M.J. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 1998, 287:187-197.
3. Banasikowski T.J., Beninger R.J. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors. Int. J. Neuropsychopharmacol. 2012, 1-10. FirstView. 10.1017/S1461145711001696.
4. Banasikowski T.J., Beninger R.J. Conditioned drug effects. Encyclopedia of Psychopharmacology 2010, 325-331. Springer, Heidelberg, Germany. I.P. Stolerman (Ed.).
5. Banasikowski T.J., Bespalov A., Drescher K., Behl B., Unger L., Haupt A., Schoemaker H., Sullivan J.P., Gross G., Beninger R.J. Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats. J. Pharmacol. Exp. Ther. 2010, 335:506-515.
6. Banasikowski T.J., Macleod L.S., Beninger R.J. Comparison of nafadotride, CNQX, and haloperidol on acquisition versus expression of amphetamine-conditioned place preference in rats. Behav. Pharmacol. 2012, 23:89-97.
7. Beninger R.J., Banasikowski T.J. Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor. Neurotox. Res. 2008, 14:57-70.
8. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
9. Boileau I., Guttman M., Rusjan P., Adams J.R., Houle S., Tong J., Hornykiewicz O., Furukawa Y., Wilson A.A., Kapur S., Kish S.J. Decreased binding of the D3 dopamine receptor-preferring ligand [11 C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
10. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3363-3367.
11. Boye S.M., Rompre P.P. Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine. J. Neurosci. 2000, 20:1229-1239.
12. Cervo L., Burbassi S., Colovic M., Caccia S. Selective antagonist at D3 receptors, but not non-selective partial agonists, influences the expression of cocaine-induced conditioned place preference in free-feeding rats. Pharmacol. Biochem. Behav. 2005, 82:727-734.
13. Cervo L., Cocco A., Petrella C., Heidbreder C.A. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int. J. Neuropsychopharmacol. 2007, 10:167-181.
14. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res. 1995, 673:242-250.
15. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 1996, 731:31-38.
16. Chiang Y.-C., Chen P.-C., Chen J.-C. D3 dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res. 2003, 972:159.
17. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 1983, 3:1607-1619.
18. Gilbert J.G., Newman A.H., Gardner E.L., Ashby C.R., Heidbreder C.A., Pak A.C., Peng X.Q., Xi Z.X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005, 57:17-28.
19. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997, 20:31-37.
20. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
21. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1997, 54:225-232.
22. Gyertyan I., Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003, 14:93-98.
23. Gyertyan I., Saghy K. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav. Pharmacol. 2004, 15:253-262.
24. Gyertyan I., Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 2007, 572:171-174.
25. Klein A., Schmidt W.J. Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behav. Pharmacol. 2003, 14:49-53.
26. Lanis A., Schmidt W.J. NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behav. Pharmacol. 2001, 12:143-149.
27. Le Foll B., Diaz J., Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003, 47:176-183.
28. Le Foll B., Frances H., Diaz J., Schwartz J.C., Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 2002, 15:2016-2026.
29. Le Foll B., Sokoloff P., Stark H., Goldberg S.R. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005, 30:720-730.
30. Liang J., Zheng X., Chen J., Li Y., Xing X., Bai Y., Li Y. Roles of BDNF, dopamine D(3) receptors, and their interactions in the expression of morphine-induced context-specific locomotor sensitization. Eur. Neuropsychopharmacol. 2011, 21:825-834.
31. Martelle J.L., Claytor R., Ross J.T., Reboussin B.A., Newman A.H., Nader M.A. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxami de] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzami de], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 321:573-582.
32. Mazurski E.J., Beninger R.J. Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology (Berl) 1991, 105:107-112.
33. Mela F., Millan M.J., Brocco M., Morari M. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. Neuropharmacology 2010, 58:528-536.
34. Millan M.J., Gressier H., Brocco M. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur. J. Pharmacol. 1997, 321:R7-R9.
35. Millan M.J., Seguin L., Gobert A., Cussac D., Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 2004, 174:341-357.
36. Mizrahi R., Agid O., Borlido C., Suridjan I., Rusjan P., Houle S., Remington G., Wilson A.A., Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11 C]-(+)-PHNO. Schizophr. Res. 2011, 131:63-68.
37. Neisewander J.L., Fuchs R.A., Tran-Nguyen L.T., Weber S.M., Coffey G.P., Joyce J.N. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004, 29:1479-1487.
38. Pak A.C., Ashby C.R., Heidbreder C.A., Pilla M., Gilbert J., Xi Z.X., Gardner E.L. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int. J. Neuropsychopharmacol. 2006, 9:585-602.
39. Pritchard L.M., Newman A.H., McNamara R.K., Logue A.D., Taylor B., Welge J.A., Xu M., Zhang J., Richtand N.M. The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol. Biochem. Behav. 2007, 86:718-726.
40. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., Boyfield I., Branch C.L., Cilia J., Coldwell M.C., Hadley M.S., Hunter A.J., Jeffrey P., Jewitt F., Johnson C.N., Jones D.N., Medhurst A.D., Middlemiss D.N., Nash D.J., Riley G.J., Routledge C., Stemp G., Thewlis K.M., Trail B., Vong A.K., Hagan J.J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294:1154-1165.
41. Riedinger K., Kulak A., Schmidt W.J., von Ameln-Mayerhofer A. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization. Behav. Brain Res. 2011, 218:194-199.
42. Sautel F., Griffon N., Sokoloff P., Schwartz J.C., Launay C., Simon P., Costentin J., Schoenfelder A., Garrido F., Mann A., et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 1995, 275:1239-1246.
43. Schmidt W.J., Beninger R.J. Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox. Res. 2006, 10:161-166.
44. Schmidt W.J., Tzschentke T.M., Kretschmer B.D. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801. Eur. J. Neurosci. 1999, 11:3365-3368.
45. Segal D.M., Moraes C.T., Mash D.C. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res. Mol. Brain Res. 1997, 45:335-339.
46. Silverdale M.A., Nicholson S.L., Ravenscroft P., Crossman A.R., Millan M.J., Brotchie J.M. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp. Neurol. 2004, 188:128-138.
47. Staley J.K., Mash D.C. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 1996, 16:6100-6106.
48. Swain S.N., Beuk J., Heidbreder C.A., Beninger R.J. Role of dopamine D3 receptors in the expression of conditioned fear in rats. Eur. J. Pharmacol. 2008, 579:167-176.
49. Valenti O., Cifelli P., Gill K.M., Grace A.A. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J. Neurosci. 2011, 31:12330-12338.
50. Vorel S.R., Ashby C.R., Paul M., Liu X., Hayes R., Hagan J.J., Middlemiss D.N., Stemp G., Gardner E.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22:9595-9603.
51. Wiecki T.V., Riedinger K., von Ameln-Mayerhofer A., Schmidt W.J., Frank M.J. A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal. Psychopharmacology (Berl) 2009, 204:265-277.
52. Xi Z.X., Gardner E.L. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 2007, 13:240-259.